The FDA cleared Diasorin’s customizable syndromic GI multiplex PCR panel, expanding the LIAISON Plex Gastrointestinal Flex Assay menu. The test detects 24 pathogens—bacteria, viruses, and parasites—and can be tailored via Diasorin’s Flex software based on factors such as seasonality and clinical presentation. Diasorin highlighted that some organism types not typically included in competing panels—such as Microsporidia, Dientamoeba fragilis, and Strongyloides stercoralis—are part of the panel, which it described as completing the core Liaison Plex portfolio. The clearance underscores intensifying competition in syndromic molecular testing, where customization and breadth increasingly function as differentiators for lab adoption.